QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

The goal of this clinical trial is to learn if QL1706 is effective in early HR+/HER2- breast cancer. It will also learn about the safety of QL1706. The main questions it aims to answer are: Does QL1706 combined with neoadjuvant chemotherapy improve the pCR rate of early HR+/HER2- breast cancer? What adverse events do participants have when receiving QL1706? Participants will: Receive QL1706 plus chemotherapy or chemotherapy every 3 weeks for 6 cycles; All patients will receive surgery, and the primary end point is pathological complete response at the time of definitive surgery; After definit

Trial Details

NCT ID
NCT06967103
Phase
PHASE2
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • QL1706
  • Nab-PE
Locations (sample)
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Subjects meeting all of the following criteria are eligible for inclusion in this study:
  • Voluntarily participates in the study, signs the informed consent form, and demonstrates good compliance.
  • Female, aged ≥18 years .
  • Evaluated by the research center as eligible to tolerate and scheduled to undergo radical breast cancer surgery, with no prior systemic anti-tumor …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →